PMC:7408073 / 343-620
Annnotations
LitCovid-PD-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T4 | 46-49 | Body_part | denotes | RAS | http://purl.obolibrary.org/obo/UBERON_0018229 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 21 | 174-177 | Gene | denotes | ACE | Gene:59272 |
| 22 | 182-186 | Gene | denotes | ACE2 | Gene:59272 |
| 27 | 98-104 | Species | denotes | humans | Tax:9606 |
| 28 | 251-259 | Species | denotes | patients | Tax:9606 |
| 32 | 242-250 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T4 | 242-250 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1177 | 98-104 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | humans |
| T48692 | 114-115 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T4 | 46-49 | Chemical | denotes | RAS | http://purl.obolibrary.org/obo/CHEBI_63620 |
| T5 | 50-68 | Chemical | denotes | pathway inhibitors | http://purl.obolibrary.org/obo/CHEBI_76932 |
| T6 | 58-68 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
| T7 | 147-157 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
| T8 | 187-191 | Chemical | denotes | zinc | http://purl.obolibrary.org/obo/CHEBI_27363|http://purl.obolibrary.org/obo/CHEBI_30185 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T5 | 0-277 | Sentence | denotes | Based purely on experimental studies in which RAS pathway inhibitors were administered in vivo to humans/rodents, a reasonable hypothesis of using inhibitors that block both ACE and ACE2 zinc metalloproteases and their downstream pathways in COVID-19 patients will be proposed. |